Risk Assessment for Aflatoxin: An Evaluation Based on the Multistage Model |
| |
| Authors: | J. Bowers B. Brown J. Springer L. Tollefson R. Lorentzen S. Henry |
| |
| Affiliation: | U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, 200 C Street, S.W., Washington, D.C. 20204. |
| |
| Abstract: | ![]()
Lifetime cancer potency of alfatoxin was assessed based on the Yeh et al. study from China in which both aflatoxin exposure and hepatitis B prevalence were measured. This study provides the best available information for estimating the carcinogenic risk posed by aflatoxin to the U.S. population. Cancer potency of aflatoxin was estimated using a biologically motivated risk assessment model. The best estimate of aflatoxin potency was 9 (mg/kg/day)−1 for individuals negative for hepatitis B and 230 (mg/kg/day)−1 for individuals positive for hepatitis B. |
| |
| Keywords: | Aflatoxin risk assessment cancer potency multistage models |
|
